Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

UK 356618 is an inhibitor of matrix metalloproteinase-3 (MMP-3; IC50 = 5.9 nM).1 It is selective for MMP-3 over MMP-1, -2, -9, -13, and -14 (IC50s = 51, 1.79, 0.84, 0.073, and 1.9 µM, respectively). UK 356618 (73 nM) inhibits IL-6-induced migration of NCI H446 small cell lung cancer (SCLC) cells in vitro.2 It reduces hyperglycemia-exacerbated increases in brain edema and hemorrhagic transformation in the cortex and striatum in a rat model of ischemia-reperfusion injury induced by middle cerebral artery occlusion (MCAO) when administered intravenously at a dose of 15 mg/kg.3
WARNING This product is not for human or veterinary use.
1. Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-
2. Interleukin 6 trigged ataxia-
3. Matrix metalloprotease 3 exacerbates hemorrhagic transformation and worsens functional outcomes in hyperglycemic stroke. Stroke 47(3), 843-851 (2016).